SAN DIEGO, Oct. 8 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX), a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, announced today that it has appointed
Mark Erwin to the new position of vice president of commercialization. Mr.
Erwin will be responsible for defining, developing and leading the
company's commercial operations.
"We are pleased to have recruited Mark to our team," said Evan M.
Levine, ADVENTRX chief executive officer. "Mark brings tremendous
experience in commercialization and oncology product launch leadership,
which will be crucial as we move forward with ANX-530, a novel emulsion
formulation of vinorelbine, for which ADVENTRX plans to submit an NDA to
the FDA next year, pending positive results from our on-going
bioequivalence study."
Most recently, Mr. Erwin served as senior director of program
development for Centric Health Finance, LLC, which offers financial
services for private practice oncologists. Other prior roles include
director of oncology marketing for Ligand Pharmaceuticals Corp. and head of
government affairs and reimbursement for IDEC Pharmaceuticals, Inc. Mr.
Erwin began his career in a variety of sales and marketing roles with Eli
Lilly & Co., including product manager for the launch of Lilly's oncology
business in the US, and he holds a degree in chemistry from Purdue
University.
About ANX-530 (vinorelbine emulsion)
ANX-530 is a novel emulsion formulation of vinorelbine tartrate, a
generic chemotherapy agent. ANX-530 is designed to reduce the incidence and
severity of vein irritation from IV-delivery of vinorelbine tartrate.
Vinorelbine tartrate works by disrupting microtubule formation and is a
member of the vinca alkaloid class of antineoplastic agents. Vinorelbine is
indicated as a single agent or in combination with cisplatin for treatment
of advanced non-small cell lung cancer and has also shown activity in
breast, ovarian, and other cancers.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can be found
on the Company's web site at http://www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other factors
that, if they do not materialize or prove to be accurate, could cause
ADVENTRX's results to differ materially from historical results or those
expressed or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that preclinical
and clinical results are not indicative of the success of subsequent
clinical trials and that products will not perform as preclinical and
clinical data suggests or as otherwise anticipated; the FDA's views on the
appropriateness of seeking marketing approval of ANX-530 under Section
505(b)(2); difficulties or delays in developing, testing, manufacturing and
marketing and obtaining regulatory approval for ANX-530, including
receiving necessary regulatory approvals for clinical trials of ANX-530 and
the potential for automatic injunctions regarding FDA approval of ANX-530
and other challenges by patent holders during the Section 505(b)(2)
process; uncertainty under Section 505(b)(2) resulting from legal action
against the FDA and the potential that future interpretations of Section
505(b)(2) could delay or prevent the FDA from approving any Section
505(b)(2) NDA; the potential for regulatory authorities to require
additional preclinical work or other clinical requirements to support
regulatory filings; patent and non-patent exclusivity covering docetaxel;
the risk that ADVENTRX will be unable to raise sufficient capital to fund
the projects necessary to meet its anticipated or stated goals and
milestones, including funding the continued development of ANX-530; and
other risks and uncertainties more fully described in ADVENTRX's press
releases and periodic filings with the Securities and Exchange Commission.
ADVENTRX's public filings with the Securities and Exchange Commission are
available at http://www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date when made. ADVENTRX does not
intend to revise or update any forward-looking statement, including as set
forth in this press release, to reflect events or circumstances arising
after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
 back to top
Related links:
http://www.adventrx.com
CONTACT:
Investors, Ioana C. Hone of ADVENTRX
Pharmaceuticals, +1-858-552-0866
|
